Sidewinder Therapeutics
Rare Disease Therapeutics · Health Care
Overview
Sidewinder Therapeutics is pioneering the next generation of large molecule precision therapeutics. We aim to deliver new life-saving therapies for patients with cancer and rare disease.
Key facts
These are the key facts about Sidewinder Therapeutics on Alion as of Nov 13, 2026. The latest round is Series B of $137M, announced in 2026.
- Employees
- 200+Alion company profile, an estimated range
- Total raised
- $137MSum of 1 equity round Alion knows
- Latest round
- Series B · $137M · Apr 7, 2026Press report · sidewinderbio.com
Funding and backers
Total raised
$137M
1 round on record
Latest round
$137M
Series B · Apr 2026 · 7 mo ago
Team
201-500
employees, estimated range
Backers
3
DCVC, Novartis Venture Fund
The money's age
Fresh money
7 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Apr 2026 | $137M | — | sidewinderbio.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Mendra is a venture-backed rare-disease biopharma accelerating the development and commercialization of de-risked breakthrough therapies.
Mahzi aims to unite patient and family groups, academic researchers, other industry members, and our internal team of experts to develop…
Explore the Kyntra Bio site to learn about our oncology and rare disease therapies, pipeline highlights, clinical trials, culture, and…
SynaptixBio is a rare disease biotech pioneering ground-breaking development for treatment of severe leukodystrophies which affect the…
Eton is an innovative pharmaceutical company that searches the world over for meaningful therapies that we can bring to patients living…
Celestial Therapeutics is developing novel therapies based on innovative and groundbreaking science to treat, prevent and cure infectious…
Financials
Total raised
$137M
Latest round
Series B
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2026 | $137M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Novartis Venture FundVia a fund
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
DCVCVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Sidewinder Therapeutics: $137 Million Raised For Bispecific ADC Cancer Therapies
Sidewinder Therapeutics, a biopharmaceutical company developing next-generation bispecific antibody-drug conjugates, announced the closing of an oversubscribed $137 million Series B financing round to advance its oncology pipeline into clinical developmen
Read more
Report
Report
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer
Read more
Report
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer
Read more
Report
Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs
Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ADC platform will enable the development of first-in-class b
Read more
Report
Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs
Read more
Report
Report
Report
How to cite this page
Alion, "Sidewinder Therapeutics: key facts", as of Nov 13, 2026. https://alion.io/company/sidewinderbio
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0